|
WDFY3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.44989584174959E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.13189995948937E-09 |
| Normal-vs-Stage2 |
2.607300E-04 |
| Normal-vs-Stage3 |
6.9651995282527E-10 |
| Normal-vs-Stage4 |
8.06289479626798E-11 |
| Stage1-vs-Stage2 |
6.091200E-01 |
| Stage1-vs-Stage3 |
4.560000E-02 |
| Stage1-vs-Stage4 |
4.819400E-04 |
| Stage2-vs-Stage3 |
7.586400E-02 |
| Stage2-vs-Stage4 |
5.537800E-03 |
| Stage3-vs-Stage4 |
1.645400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.82338646590597E-12 |
| Normal-vs-AfricanAmerican |
9.801600E-03 |
| Normal-vs-Asian |
1.95699999999688E-05 |
| Caucasian-vs-AfricanAmerican |
1.295430E-01 |
| Caucasian-vs-Asian |
3.605600E-01 |
| AfricanAmerican-vs-Asian |
4.537000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.26160004665365E-09 |
| Normal-vs-Female |
2.89789969798449E-10 |
| Male-vs-Female |
6.787200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.36799999503634E-08 |
| Normal-vs-Age(41-60Yrs) |
5.21529996966308E-09 |
| Normal-vs-Age(61-80Yrs) |
6.69089994520533E-09 |
| Normal-vs-Age(81-100Yrs) |
2.343800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.400200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.369900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.873400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.363600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.918200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.933800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.121440E-03 |
| Classical-VS-Follicular |
9.333800E-01 |
| Classical-VS-Other |
7.093200E-01 |
| Classical-VS-Normal |
9.97140000014163E-07 |
| Tall-VS-Follicular |
8.696000E-03 |
| Tall-VS-Other |
2.632600E-01 |
| Tall-VS-Normal |
1.12349995973204E-09 |
| Follicular-VS-Other |
7.719400E-01 |
| Follicular-VS-Normal |
1.52975999999638E-05 |
| Other-VS-Normal |
2.346300E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.21710000042941E-09 |
| Normal-vs-N1 |
2.59429999704963E-08 |
| N0-vs-N1 |
2.187400E-01 |
|
|
